Introduction
============

Each pregnancy represents a unique and remarkable challenge to the mother's immune system, as her body must accept and carry a fetus to term without immune rejection. Immunological tolerance during pregnancy is necessary for women's bodies to accept the fetus.[@b1-clep-10-931],[@b2-clep-10-931] This obligate tolerance has been observed for many years, and because of it, each fetus can be seen as a different semi-allograft. Interestingly, "immune evasion", which consists of some similar immunological changes, was included as another hallmark of cancer,[@b3-clep-10-931] and researchers have recognized some common characteristics between these two highly different biological processes.[@b4-clep-10-931]--[@b7-clep-10-931] Looking at this, it seems paradoxical that increasing number of full-term pregnancies reduces the risk of breast cancer (BC) in women.[@b8-clep-10-931],[@b9-clep-10-931] Some studies have even shown a protective effect up to eight or nine children.[@b8-clep-10-931] However, neither spontaneous nor induced abortions confer the same risk reduction.[@b10-clep-10-931],[@b11-clep-10-931]

The role of hormones is well established in both pregnancy and tumorigenesis; however, the influence of hormonal fluctuations associated with pregnancy on the cancer development in a long-term perspective remains unclear.[@b12-clep-10-931],[@b13-clep-10-931] High, changing levels of hormones such as estrogens, gestagens, and human chorionic hormone initiate and support immunological tolerance during pregnancy,[@b14-clep-10-931] whereas the high levels of estrogens and progestins found in oral contraceptives and hormone replacement therapy are classified as carcinogens.[@b15-clep-10-931]

We have previously shown that blood gene expression profiles differ between women with BC and BC-free controls, both at time of diagnosis[@b16-clep-10-931] and during the years prior to diagnosis.[@b17-clep-10-931] Additionally, in a recent study, we compared gene expression in blood and breast tumor tissue.[@b18-clep-10-931] We revealed some similarities in expression profiles mainly for immunogenic tumors; however, we demonstrated that there is no obligate common gene expression pattern.

Here, we aim to explore changes in blood gene expression in women with BC and cancer-free controls according to number of full-term pregnancies (FTPs).

Methods
=======

Norwegian Women and Cancer (NOWAC) study
----------------------------------------

The NOWAC study[@b19-clep-10-931] is a national population-based study in which a random sample of women living in Norway was recruited starting in 1991. Among the 172,748 women invited to participate, 165,227 women replied to at least one questionnaire and make up the study population. Death and emigration status of these women were updated through linkage to the Cause of Death Registry at Statistics Norway and Central Population Registry, respectively. Information on parity was taken from the NOWAC questionnaires. The date of entry into the present study was set as the date of the first questionnaire answered. The exit date from NOWAC was determined either by the date of cancer diagnosis or end of follow-up (2013/12/31). The NOWAC postgenome cohort consisted of 48,692 women randomly sampled from the whole NOWAC study, born in 1943--1957, with a blood sample buffered to preserve the gene expression profile (PAXgene Blood RNA system; Preanalytix/Qiagen, Hilden, Germany). The NOWAC postgenome biobank contained blood samples from women taken by local physicians and mailed overnight to the study center in Tromsø. The blood was collected in 2003--2006.[@b20-clep-10-931] BC cases that were diagnosed in 2003--2009 were identified through linkage to the National Cancer Registry of Norway. Altogether 546 cases were identified prospectively, ie, developed BC after blood sample donation.

For each BC case, a control from the NOWAC post-genome cohort was assigned, matched by time of blood sampling and year of birth, to be analyzed together with the case. The controls were used to establish the average (mean) gene expression in individuals without cancer and to serve as the basis for exposure-adjusted analyses. The expression level of a gene not involved in the carcinogenic process varied depending on day-to-day changes in exposures such as environment and nutrition, resulting in random fluctuations of the difference in gene expression between cases and matched controls around a population-average constant over time. On the other hand, the difference in the expression of genes related to different stages of the carcinogenic process varied over time in a nonrandom way, thus exhibiting a nonrandom trend. Moreover, the changes in the expression of genes related to the carcinogenesis could be complicated by other effects caused by exposure to carcinogens.

Laboratory procedures
---------------------

All extraction and microarray services were provided by the Genomics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway. To control for technical variability such as different batches of reagents and kits, day-to-day variations, microarray production batches, and effects related to different laboratory operators, each case--control pair was kept together throughout all extraction, amplification, and hybridization procedures. RNA extraction was performed using the PAXgene Blood mRNA Isolation kit (Preanalytix/Qiagen) according to the manufacturer's instructions. RNA quality and purity were assessed using the NanoDrop ND 8000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), respectively. RNA amplification was performed on 96-well plates using 300 ng of total RNA and the Illumina TotalPrep-96 RNA Amplification Kit (Ambio, Inc., Austin, TX, USA). The amplification procedure consisted of reverse transcription with a T7 promoter and ArrayScript, followed by a second-strand synthesis. In vitro transcription with T7 RNA polymerase using a biotin--nucleoside triphosphates mix produced biotinylated cRNA. All case--control pairs were run on either the IlluminaHumanAWG-6 version 3 expression bead chips or the HumanHT-12 version 4 expression bead chips. Outliers were excluded after visual examination of dendrograms, principal component analysis (PCA) plots and density plots. Individuals who were considered borderline outliers were excluded if their laboratory quality measures were below given thresholds (RNA integrity number value \<7, 260/280 ratio \<2, 260/230 ratio \<1.7, and 50 \< RNA \< 500).

Statistical methods
-------------------

The first stage of the analysis was to explore the relationship between full-term pregnancies and BC in the whole NOWAC cohort. Based on person-years, the percentage change in incidence rates of BC for each additional child was calculated by using a Poisson linear regression. Each covariate was analyzed separately in a stratified analysis with test for interactions using the Wald test. A Cox proportional semiparametric hazard analysis with attained age as follow-up was used for estimating the overall effect of potential confounders.

Then, gene expression profiles were analyzed for BC cases and controls using microarray technology. The dataset with 30,046 probes for each individual was preprocessed as previously described.[@b21-clep-10-931] The dataset was background corrected using negative control probes, log~2~ transformed using a variance stabilizing technique,[@b22-clep-10-931] and quantile normalized. Data from the two Illumina chips (HumanWG-6 v3 and HumanHT-12 v4) were combined on identical nucleotide universal identifiers.[@b23-clep-10-931] We retained probes present in at least 70% of the individuals. If a gene was represented with more than one probe, the average expression level of the probes was used as the expression for the gene, resulting in a dataset with 8155 genes. The probes were translated to genes using the lumiHumanIDMapping database.[@b24-clep-10-931] Finally, the differences in the log~2~ gene expression for each case--control pair were computed and used in the statistical analyses. We then excluded 79 case--control pairs in which the case was diagnosed with in situ BC and seven pairs in which the controls were diagnosed with BC before the end of follow-up in 2014. The final preprocessed dataset included 460 case--control pairs.

A nested case--control design was chosen in order to reduce batch effects in the laboratory. In PCA plots, we observed no batch effects in the data that were obtained after we computed differences in log2 gene expression between cases and controls. We used the Bioconductor R-package Limma (linear models for microarrays) to identify the genes that were influenced by parity.[@b25-clep-10-931] In the linear model, the responses were the differences in the log~2~ gene expression for each case--control pair, while we included the parity of the control and the parity of the case as covariates. In the analyses, we merged parities 1--3 and 4--6 so that the parity data consisted of three different values: 0, 1--3, and 4--6. The merging was made in order to reduce the effect of the highest parities. The distribution of parities for cases and controls included in this study is shown in [Table S1](#SD1-clep-10-931){ref-type="supplementary-material"}. We identified gene sets that were influenced by parity using Limma in the same way as we did for individual genes by using enrichment scores for gene sets instead of differences in the log~2~ gene expressions as responses in the linear model. The enrichment scores for gene sets were obtained from the differences in log~2~ gene expressions using the Bioconductor R-package gene set variation analysis (GSVA).[@b26-clep-10-931]

Ethics approval and consent to participate
==========================================

The NOWAC study was approved by the Norwegian Data Inspectorate and the Regional Ethical Committee of North Norway (REK). The study was conducted in compliance with the Declaration of Helsinki, and all participants gave written informed consent. The linkages of the NOWAC database to national registries such as the Cancer Registry of Norway and registries on death and emigration were approved by the Directorate of Health. The women were informed about these linkages. Furthermore, the collection and storing of human biological material was approved by the REK in accordance with the Norwegian Biobank Act. Women were informed in the letter of introduction that the blood samples would be used for gene expression analyses.

Results
=======

Reduction of BC risk after full-term pregnancies
------------------------------------------------

Our first step was to estimate the mathematical relationship between parity and BC incidence in the complete NOWAC cohort, which consisted of 165,227 participants and 6536 registered incident BC cases identified through linkage to the Cancer Registry of Norway. Increasing parity was related to less BC in mothers, less use of hormone replacement therapy, larger body mass index (BMI), earlier first birth, more breast feeding, and less use of oral contraceptives ([Table 1](#t1-clep-10-931){ref-type="table"}). Among both premenopausal and postmenopausal women, a regular decrease in incidence rates was found ([Figure 1](#f1-clep-10-931){ref-type="fig"} and [Table S2](#SD2-clep-10-931){ref-type="supplementary-material"}), and in linear regression analyses of BC incidence in the complete NOWAC cohort, each new pregnancy conferred a strong linear reduction in the absolute risk (8.0%; [Figure 1](#f1-clep-10-931){ref-type="fig"}). This led to an observed reduction of 48% for a woman with six children.

Differences in BC incidence rates were of the same order between nulliparous and uniparous women and for women with five or six children, illustrating an additive effect. The linearity of BC incidence was equally clear regardless of menopausal status, showing the persistent effect of age, but postmenopausal women had higher BC incidence rates ([Figure 1](#f1-clep-10-931){ref-type="fig"}). Stratification on all risk factors (current use of hormone replacement therapy, BMI, age at first birth, breastfeeding, ever use of oral contraceptives, and maternal history of BC) revealed the same linear patterns ([Table S3](#SD1-clep-10-931){ref-type="supplementary-material"}). There were no significant interactions between different strata of the risk factors (none in the Wald test). Using the Cox's multivariate hazard model adjusted for the same risk factors (taken from [Table S3](#SD3-clep-10-931){ref-type="supplementary-material"}), the crude estimated relative risk (RR) in women with six children versus nulliparous women was 0.50 (95% CI 0.37--0.66) and adjusted RR was 0.49 (95% CI 0.36--0.68), similar to the ones derived from Poisson regression analysis ([Table S4](#SD4-clep-10-931){ref-type="supplementary-material"}).

Differential pregnancy-associated blood gene expression between cases and controls
----------------------------------------------------------------------------------

This linear relationship independent of other covariates was then used to test the hypothesis that blood gene expression of some genes increased or decreased linearly according to parity.

An overall analysis without parity status showed no significant differences in expressed genes between cases and controls. When we added one parity variable for the cases and one for the controls in the model, we found a significant linear relationship between log gene expression and parity for 756 genes in BC-free controls, but we found no such relationship in BC cases (false discovery rate \[FDR\] 5%). Among the controls, 96 of 756 significant genes had at least 5% change per child (91 were upregulated and five were downregulated) and four genes had at least 10% change per child (all were upregulated). A description of potential carcinogenic effects in BC of the ten top significant genes showed ([Table 2](#t2-clep-10-931){ref-type="table"}) that four of them are tumor promoter genes and one is a tumor suppressor gene; however, the function of five significant genes was unknown.

Gene set enrichment analysis
----------------------------

[Table 3](#t3-clep-10-931){ref-type="table"} demonstrates the results of gene set enrichment analysis. We identified 588 gene sets from the C7 collection in Molecular Signatures Database (MSigDB; <http://software.broadinstitute.org/gsea/index.jsp>)[@b27-clep-10-931] that were significantly enriched when the parity of the controls varied (FDR 5%). Experimentally produced gene sets were submitted to MSigDB from researchers using both in vivo and in vitro materials, as well as both human cells or tissues and animal models. Of our 588 enriched gene sets, 215 were derived from human data and 373 were derived mostly from mouse data.

Detailed characterization of the top 10 gene sets from each species showed a discrepancy in the tissues analyzed: blood and cord blood in humans versus bone marrow and spleen in mice ([Tables 4](#t4-clep-10-931){ref-type="table"} and [S5](#SD5-clep-10-931){ref-type="supplementary-material"}). We had information on gender for only one of the top 10 human gene sets and four of the mouse gene sets (after contacting main authors of the associated publications). None of the MSigDB gene sets from either humans or mice included information on the number of full-term pregnancies ([Table 4](#t4-clep-10-931){ref-type="table"}).

Discussion
==========

We suggest that our unexpected finding of no changes in gene expression levels from circulating immune-competent cells in BC cases as opposed to parity-dependent changes in healthy women might be linked to the long-term immune-related protection against BC conferred by semi-allograft experience of each pregnancy. Our findings demonstrating the 8% decrease in BC risk for each birth correspond well to a number of previously published studies.[@b8-clep-10-931],[@b9-clep-10-931]

The systems epidemiology approach we used is based on an integrated analysis in the same cohort; first, hypotheses describing the mathematical relationship between parity and BC incidence in the whole NOWAC study are explored. The findings were that the linear relationship between parity and BC could be described as independent of other risk factors. Then, this hypothesis was tested using gene expression profiles obtained from the postgenome biobank of NOWAC. Consequently, we reduced the number of multiple testing in the gene expression analysis and the potential for false-positive findings.

In a recent analysis of interactions between gene expression in BC tissues and blood samples nested in the NOWAC postgenome study,[@b18-clep-10-931] we found that genes expressed in tumors and used as markers are not necessarily expressed in a similar manner in blood. Not surprisingly, tumors were enriched for genes related to cancer hallmarks, while in blood, the genes represented either general cellular or immune-related processes.

Currently, there is no unifying concept explaining mechanism of pregnancy-related BC protection. Yet, four main theories may be underlined: decreased number of mammary stem cells, changes in circulating hormone levels, differentiation of breast epithelial cells, and altered estrogen responsiveness.[@b28-clep-10-931] Notably, most of these theories are based on studies focusing on the local changes in the mammary gland, while we used blood samples as the source of data, thus looking at systemic processes.

The single-gene analysis revealed a set of genes linearly changing expression after pregnancies in controls. Almost all of these genes were upregulated. This parity-dependent effect was nonsignificant when we compared all cases and controls without taking parity status into account. A possible explanation could be the low parity in the study population with two children as the median value. Of the top ten significant genes, four upregulated genes were known to be related to breast carcinogenesis.[@b29-clep-10-931]--[@b32-clep-10-931] Similar to our results, one study found lower levels of TFRC in plasma of BC cases compared to controls.[@b33-clep-10-931] However, the overall meaning of these expression changes in healthy women is uncertain.

Previously, Rotunno et al[@b34-clep-10-931] demonstrated the significant enrichment of inflammatory and immune response genes in parous women compared to nulliparous. In our gene set enrichment analysis, we observed significant enrichment of numerous gene sets related to the immune system (C7 collection in MSigDB). It is nearly impossible to make an unambiguous conclusion from these results due to the complexity of gene sets' data and lack of essential information in gene sets' description (eg, we were unable to ascertain the gender of blood donors for the majority of human experiments even after contacting the authors of publications). Nevertheless, we observed a clear interspecific difference between components of the immune system: the gene sets were related to (in mice, most of the gene sets were of innate immunity origin, while in humans, they were of adaptive origin) and between the sources of the cells for the experiments. While the latter can be explained by technical and ethical considerations, the former raises yet another concern on the validity of results obtained in animal models.[@b35-clep-10-931]--[@b39-clep-10-931]

Pregnancy and cancer share multiple characteristics including proliferation, invasion, neoangiogenesis, and modulation of local and systemic immune response.[@b4-clep-10-931] Indeed, in our study, we observed that women with a high parity have a higher expression of tumor promoter genes and a lower expression of tumor suppressor genes; therefore, we propose that the body might experience each pregnancy as a "pseudo cancer". It is possible to suggest that some pregnancy-related processes may have common genetic signatures and protein expression profile with initial stages of breast tumor formation. Being securely controlled by a variety of local and systemic mechanisms during pregnancy, the immune system does not respond to the changes in breast tissue, while storing memory and effector cells. Later, these cells can initiate rapid and extensive response against cancer cells during the early stages of carcinogenesis. This phenomenon of long-term storage of various subsets of antigen-experienced immune cells after pregnancies has previously been described.[@b40-clep-10-931],[@b41-clep-10-931] Slight expressional differences in each pregnancy expand the pool of antigen-specific immune cells, thus increasing protective effect with the number of pregnancies. Recently, Krause et al[@b42-clep-10-931] published an experimental study confirming our hypothesis.

Our findings of an impaired immune surveillance in BC patients opposed to healthy women may generate novel approaches to immunotherapy based on the natural mechanisms involved in amplified protection against BC with repeated pregnancies. Deciphering of these mechanisms could significantly improve response rate of BC patients to immunotherapy, which at present remains poor.[@b43-clep-10-931]--[@b45-clep-10-931]

The major weakness of the study is the lack of statistical power for the gene expression analyses. However, this was compensated by the strict hypothesis testing approach. The strength of the design is the complete follow-up on cancer, emigration, and mortality based on a unique national birth number. The external validity of the parity data in NOWAC was found to be excellent in a linkage study based on information from the fertility register in Statistics Norway.[@b46-clep-10-931]

Conclusion
==========

To our knowledge, this is the first study revealing the involvement of the immune system in parity-associated BC protection with the use of systems epidemiology approach. Owing to descriptive study design, it is not possible to hypothesize the exact mechanisms responsible for the pregnancy-associated protection from BC using data obtained in this work. Our focus on systemic rather than on local changes may provide the scientific community with a fresh view on the biology of BC and may become a foundation for future research.

Data sharing statement
======================

The datasets are stored at the European Genome-phenome Archive with accession number EGAD00010001062.

Supplementary materials
=======================

###### 

Distribution of parities for the cases and controls

             Parities                                 
  ---------- ---------- ---- ----- ----- ---- --- --- -----
  Cases      69         67   208   83    29   4   0   460
  Controls   74         62   174   116   26   5   3   460

###### 

BC cases, PY, and incidence rates per 100,000 PY, according to menopausal status and parity

  Status              Parity                                                     
  ------------------- --------- --------- --------- --------- --------- -------- --------
  **Premenopause**                                                               
  Cases               168       219       688       358       86        13       2
  PY                  7,6189    101,736   356,276   212,648   55,512    12,065   2744
  Rates               220.50    215.26    193.11    168.35    154.92    107.75   72.88
  **Postmenopause**                                                              
  Cases               535       618       2082      1254      372       95       27
  PY                  132,262   172,437   636,545   420,991   144,901   43,189   13,662
  Rates               404.50    358.39    327.08    297.87    256.73    219.97   197.62
  **Total**                                                                      
  Cases               703       837       2770      1612      458       108      29
  PY                  20,8451   274,173   992,821   633,639   200,413   55,253   16,407
  Rates               337.25    305.28    279.00    254.40    228.53    195.46   176.76

**Note:** Data from the entire NOWAC cohort.

**Abbreviations:** BC, breast cancer; NOWAC, Norwegian Women and Cancer; PY, person-years.

###### 

Tests for linear trend between strata of risk factors

  Stratification                    \% decrease per child   Intercept   *β*      Pr \> \|*t*\|*β*
  --------------------------------- ----------------------- ----------- -------- ------------------
  **Percentage change per child**                                                
  Overall                           8                       334.34      −26.84   \<0.001
  **Stratified according to:**                                                   
  Premenopause                      11                      236.4       −24.86   \<0.001
  Postmenopause                     9                       398.29      −34.57   \<0.001
  With mother history of BC         10                      631.76      −61.68   0.01
  Without mother history of BC      8                       317.59      −24.56   \<0.001
  Age at first birth \<25 years     7                       305.73      −22.4    0.002
  Age at first birth ≥25 years      6                       341.39      −20.93   0.06
  BMI \<25 kg/m^2^                  9                       337.08      −28.81   \<0.001
  BMI ≥25 kg/m^2^                   8                       333.51      −25.09   \<0.001
  Use of OC                         6                       323.64      −20.76   \<0.001
  No use of OC                      9                       340.42      −30.21   \<0.001
  No lactation                      11                      340.34      −35.78   0.022
  Years of lactation: 1--2          9                       340.61      −30.33   0.002
  Years of lactation: 3+            14                      488.44      −68.55   0.017
  HRT (only postmenopause)          9                       530.49      −49.27   0.009
  No HRT (only postmenopause)       9                       377.31      −32.77   \<0.001

**Note:** Data from the entire NOWAC cohort.

**Abbreviations:** BC, breast cancer; BMI, body mass index; HRT, hormone replacement therapy; NOWAC, Norwegian Women and Cancer; OC, oral contraceptives; Pr, probability.

###### 

Age-adjusted and multivariate-adjusted Cox proportional hazard ratios and 95% CIs for BC according to parity in the entire NOWAC cohort

  Parity   BC                  
  -------- ------------------- -------------------
  1        0.91 (0.82--1.00)   0.86 (0.77--0.96)
  2        0.81 (0.75--0.88)   0.75 (0.68--0.83)
  3        0.73 (0.68--0.80)   0.68 (0.61--0.76)
  4        0.63 (0.56--0.71)   0.59 (0.51--0.67)
  5        0.52 (0.43--0.64)   0.49 (0.39--0.62)
  6+       0.50 (0.37--0.66)   0.49 (0.36--0.68)

**Note:**

Adjustment for maternal history of BC (yes, no), BMI (\<25, 25+ kg/m^2^), current use of hormone replacement therapy (yes, no), years of lactation (0, 1--2, 2+), and use of oral contraceptives (ever used oral contraceptives, never used contraceptives).

**Abbreviations:** BC, breast cancer; BMI, body mass index; CI, confidence interval; NOWAC, Norwegian Women and Cancer.

###### 

Full names of gene sets described in [Table 4](#t4-clep-10-931){ref-type="table"}

  Human
  ---------------------------------------------------------------------
  GSE3982_CTRL_VS_LPS_4H_MAC_UP
  GSE2770_UNTREATED_VS_ACT_CD4_TCELL_48H_DN
  GSE16385_MONOCYTE_VS_12H_ROSIGLITAZONE_TREATED_MACROPHAGE_UP
  GSE1460_CORD_VS_ADULT_BLOOD_NAIVE_CD4_TCELL_DN
  GSE13411_IGM_VS_SWITCHED_MEMORY_BCELL_UP
  GSE2770_UNTREATED_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_6H_UP
  GSE29618_LAIV_VS_TIV_FLU_VACCINE_DAY7_PDC_DN
  GSE17974_2.5H_VS_72H_IL4_AND_ANTI_IL12_ACT_CD4_TCELL_UP
  GSE2770_TGFB_AND_IL4_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_2H_UP
  GSE29615_CTRL_VS_DAY3_LAIV_IFLU_VACCINE_PBMC_DN
  **Mouse**
  GSE17721_LPS_VS_PAM3CSK4_4H_BMDM_DN
  GSE14769_UNSTIM_VS_240MIN_LPS_BMDM_UP
  GSE3691_IFN_PRODUCING_KILLER_DC_VS_PLASMACYTOID_DC_SPLEEN_DN
  GSE37301_HEMATOPOIETIC_STEM_CELL_VS_COMMON_LYMPHOID_PROGENITOR_DN
  GSE32034_UNTREATED_VS_ROSIGLIZATONE_TREATED_LY6C_HIGH_MONOCYTE_DN
  GSE17721_LPS_VS_PAM3CSK4_1H_BMDM_UP
  GSE21063_WT_VS_NFATC1_KO_BCELL_DN GSE11924_TFH_VS_TH17_CD4_TCELL_UP
  GSE28237_EARLY_VS_LATE_GC_BCELL_UP
  GSE13547_CTRL_VS_ANTI_IGM_STIM_ZFX_KO_BCELL_2H_DN
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###### 

Description of the entire study population according to parity

  Characteristics                              Parity (number of children)                 
  -------------------------------------------- ----------------------------- ------ ------ ------
  Maternal history of BC                       5.9                           5.2    5.2    4.5
  Current use of hormone replacement therapy   17.4                          17.1   14.7   12.7
  BMI \<25 kg/m^2^                             58.7                          58.5   53.7   43.8
  Age at first birth \<25 years                NA                            53.2   70.8   82.2
  Years of lactation                                                                       
   Never                                       100.0                         7.8    4.1    3.1
   \<2 years                                   NA                            88.3   69.5   47.8
   2+                                          NA                            3.8    26.4   49.1
  Ever use of oral contraceptives              47.6                          59.6   52.7   37.5

**Note:** Numbers represent a percentage of women within the corresponding parity category.

**Abbreviations:** BC, breast cancer; BMI, body mass index; NA, data not available.

###### 

Top 10 single genes ranked according to *q*-value with logFC and their role in BC

  Gene ID      logFC[a](#tfn3-clep-10-931){ref-type="table-fn"}   *q*-value[b](#tfn4-clep-10-931){ref-type="table-fn"}   Role in BC   Function
  ------------ -------------------------------------------------- ------------------------------------------------------ ------------ --------------------------------------------------------------------------------------------------------------
  *CNOT8*      0.064                                              0.013                                                  TP           Involved in translation and transcription regulation
  *ZRANB2*     0.140                                              0.013                                                  NA           Protein regulating alternative splicing; exact function is unknown
  *TFRC*       0.080                                              0.013                                                  TP           Required for transfer of iron into cells from transferrin
  *CD47*       0.105                                              0.013                                                  TP           Involved in many cellular processes including proliferation, migration, and apoptosis
  *PSORS1C1*   −0.039                                             0.013                                                  NA           Function is not known. Mutations are associated with psoriasis, systemic sclerosis, and rheumatoid arthritis
  *EML4*       0.073                                              0.013                                                  NA           Protein involved in microtubule formation
  *FKBPL*      −0.027                                             0.013                                                  TS           A wide range of functions including cell cycle regulation, trafficking, and angiogenesis inhibition
  *HACL1*      0.044                                              0.013                                                  NA           Exact role is unclear. Catalyzes a carbon--carbon cleavage reaction. Involved in lipid metabolism
  *PPP1R2*     0.093                                              0.017                                                  NA           Serine/threonine phosphatase. Function is not known
  *LPIN1*      0.075                                              0.017                                                  TP           Protein controlling the metabolism of fatty acids. Transcriptional coactivator

**Notes:**

logFC is the estimated log-fold change in gene expression when the parity increases with one.

*q*-value is an FDR-adjusted *p*-value.

**Abbreviations:** BC, breast cancer; FDR, false discovery rate; NA, data not available; TP, tumor promoter; TS, tumor suppressor.

###### 

Gene set enrichment analyses for all gene sets included in MSigDB

  Collection name               All gene sets   Significant gene sets (FDR 5%)                      
  ----------------------------- --------------- -------------------------------- ------ ----- ----- -----
  C1: positional gene sets      326             326                              0      75    75    0
  C2: curated gene sets         4729            3750                             979    280   229   51
  C3: motif gene sets           836             835                              1      22    0     22
  C4: computational gene sets   858             857                              1      217   217   0
  C5: gene ontology gene sets   6166            6162                             4      0     0     0
  C6: oncogenic signatures      189             144                              45     42    35    7
  C7: immunologic signatures    4872            1844                             3028   588   215   373

**Note:** In non-human gene sets, mice are the dominant species (<http://software.broadinstitute.org/gsea/msigdb/index.jsp> MSigDB v5.2). Copyright ©2018. Dove Medical Press. Reproduced from Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005;102(43):15545--50.27.[@b27-clep-10-931]

**Abbreviations:** FDR, false discovery rate; MSigDB, Molecular Signatures Database.

###### 

Top 10 gene sets for humans and mice with information on experimental design

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  geneSetID   scoreDiff[a](#tfn8-clep-10-931){ref-type="table-fn"}   FDR\          Source            Immune system   Parity   Cells          Gender
                                                                     (*q*-value)                                                             
  ----------- ------------------------------------------------------ ------------- ----------------- --------------- -------- -------------- --------
  **Human**                                                                                                                                  

  GSE3982     0.023                                                  0.027         Cord blood        I               NA       Macrophages    NA

  GSE2770     −0.026                                                 0.027         Cord blood        A               NA       CD4+ T cells   NA

  GSE16385    0.047                                                  0.027         Blood             I               NA       Monocytes      NA

  GSE1460     0.034                                                  0.027         Cord blood\       A               NA       CD4+ T cells   NA
                                                                                   Blood                                                     

  GSE13411    −0.035                                                 0.027         Spleen            A               NA       B cells        M, F

  GSE2770     0.027                                                  0.027         Cord blood        A               NA       CD4+ T cells   NA

  GSE29618    −0.029                                                 0.027         Blood             I               NA       DC             NA

  GSE17974    0.028                                                  0.027         Cord blood        A               NA       CD4+ T cells   NA

  GSE2770     −0.028                                                 0.027         Cord blood        A               NA       CD4+ T cells   NA

  GSE29615    0.038                                                  0.027         Blood             I, A            NA       PBMCs          NA

  **Mouse**                                                                                                                                  

  GSE17721    0.018                                                  0.027         Bone marrow       I               NA       DC             F

  GSE14769    0.032                                                  0.027         Bone marrow       I               NA       Macrophages    NA

  GSE3691     0.037                                                  0.027         Various tissues   I               NA       DC             F

  GSE37301    0.035                                                  0.027         Bone marrow       I, A            NA       HSCs, CLPCs    NA

  GSE32034    0.028                                                  0.027         Various tissues   I               NA       Monocytes      M

  GSE17721    0.026                                                  0.027         Bone marrow       I               NA       DC             F

  GSE21063    0.036                                                  0.027         Spleen            A               NA       B cells        NA

  GSE11924    −0.029                                                 0.027         Spleen            A               NA       CD4+ T cells   NA

  GSE28237    0.035                                                  0.027         Spleen            A               NA       B cells        NA

  GSE13547    0.034                                                  0.027         Spleen            A               NA       B cells        NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

scoreDiff is the estimated change in enrichment score when the parity increases with one.

**Abbreviations:** A, adaptive immune system; CLPCs, common lymphoid progenitor cells; DC, dendritic cells; F, female; FDR, false discovery rate; HSCs, hematopoietic stem cells; I, innate immune system; M, male; NA, data not available; PBMCs, peripheral blood mononuclear cells.
